Healthcare provider profile · identity verified

Remi Rosenberg, MD

Internal Medicine · STAMFORD, CT · NPI 1932204203

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	308	73
Amlodipine Besylate	Amlodipine Besylate	185	38
Eliquis	Apixaban	151	23
Metoprolol Succinate	Metoprolol Succinate	147	28
Sertraline Hcl	Sertraline Hcl	145	22
Omeprazole	Omeprazole	129	31
Levothyroxine Sodium	Levothyroxine Sodium	124	26
Famotidine	Famotidine	114	28
Rosuvastatin Calcium	Rosuvastatin Calcium	96	25
Tamsulosin Hcl	Tamsulosin Hcl	90	28
Losartan Potassium	Losartan Potassium	89	22
Zolpidem Tartrate	Zolpidem Tartrate	82	25
Furosemide	Furosemide	80	23
Gabapentin	Gabapentin	76	18
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	75	49
Donepezil Hcl	Donepezil Hcl	71	13
Escitalopram Oxalate	Escitalopram Oxalate	67	13
Hydrochlorothiazide	Hydrochlorothiazide	66	16
Meloxicam	Meloxicam	59	25
Metformin Hcl	Metformin Hcl	56	14
Metformin Hcl Er	Metformin Hcl	56	15
Trazodone Hcl	Trazodone Hcl	55	20
Myrbetriq	Mirabegron	50	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	50	suppressed
Irbesartan	Irbesartan	49	suppressed
Duloxetine Hcl	Duloxetine Hcl	47	12
Lisinopril	Lisinopril	47	suppressed
Allopurinol	Allopurinol	46	suppressed
Prednisone	Prednisone	43	18
Valsartan	Valsartan	42	11
Torsemide	Torsemide	40	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	37	suppressed
Simvastatin	Simvastatin	37	suppressed
Mirtazapine	Mirtazapine	36	suppressed
Alprazolam	Alprazolam	35	11
Synthroid	Levothyroxine Sodium	33	suppressed
Tramadol Hcl	Tramadol Hcl	32	13
Metoprolol Tartrate	Metoprolol Tartrate	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	29	suppressed
Estradiol	Estradiol	28	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Finasteride	Finasteride	27	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Breo Ellipta	Fluticasone/Vilanterol	24	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	17
Dexlansoprazole Dr	Dexlansoprazole	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Azithromycin	Azithromycin	20	18
Bupropion Hcl	Bupropion Hcl	20	suppressed
Cephalexin	Cephalexin	20	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	20	suppressed
Rivastigmine	Rivastigmine	19	suppressed
Levetiracetam	Levetiracetam	18	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	18	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	17	suppressed
Carvedilol	Carvedilol	17	suppressed
Potassium Chloride	Potassium Chloride	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	13
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	suppressed
Dalfampridine Er	Dalfampridine	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Lubiprostone	Lubiprostone	13	suppressed
Methylprednisolone	Methylprednisolone	13	12
Montelukast Sodium	Montelukast Sodium	13	suppressed
Amoxicillin	Amoxicillin	12	suppressed
Diltiazem 24hr Er (La)	Diltiazem Hcl	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Nebivolol Hcl	Nebivolol Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error